Abstract
Heterotrimeric G proteins of the G12 family regulate the Rho GTPase through RhoGEFs that contain an amino-terminal regulator of G protein signaling (RGS) domain (RGS-RhoGEFs). Direct regulation of the activity of RGS-RhoGEFs p115 or leukemia-associated RhoGEF (LARG) by Gα13 has previously been demonstrated. However, the precise biochemical mechanism by which Gα13 stimulates the RhoGEF activity of these proteins has not yet been well understood. Based on the crystal structure of Gαi1 in complex with RGS4, we mutated the Gα13 residue lysine 204 to alanine (Gα13K204A) and characterized the effect of this mutation in its regulation of RGS-RhoGEFs p115 or LARG. Compared with wild-type Gα13, Gα13K204A induced much less serum-response factor activation when expressed in HeLa cells. Recombinant Gα13K204A exhibits normal function in terms of nucleotide binding, basal GTP hydrolysis, and formation of heterotrimer with βγ. We found that lysine 204 of Gα13 is important for interaction with the RGS domain of p115 or LARG and for the GTPase-activating protein activity of these proteins. In addition, the K204A mutation of Gα13 impaired its regulation of the RhoGEF activity of p115 or LARG. We conclude that lysine 204 of Gα13 is important for interaction with RGS-RhoGEFs and is critically involved in the regulation of their activity.
- Received May 3, 2004.
- Accepted July 13, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|